{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:23:44Z","timestamp":1785029024570,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ygyno.2012.11.011","type":"journal-article","created":{"date-parts":[[2012,12,27]],"date-time":"2012-12-27T10:46:17Z","timestamp":1356605177000},"page":"1-2","source":"Crossref","is-referenced-by-count":4,"title":["Identifying prognostic signatures in the blood of ovarian cancer patients"],"prefix":"10.1016","volume":"128","author":[{"given":"Gerhardt","family":"Attard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.11.011_bb0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-012-0041-9","article-title":"Bevacizumab in the treatment of ovarian cancer","volume":"29","author":"Heitz","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.ygyno.2012.11.011_bb0010","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ygyno.2012.11.011_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2159-8290.CD-12-0222","article-title":"Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer","volume":"2","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ygyno.2012.11.011_bb0020","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.ygyno.2012.11.011_bb0025","doi-asserted-by":"crossref","first-page":"9393","DOI":"10.1073\/pnas.0402993101","article-title":"HER-2 gene amplification can be acquired as breast cancer progresses","volume":"101","author":"Meng","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"136","key":"10.1016\/j.ygyno.2012.11.011_bb0030","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ygyno.2012.11.011_bb0035","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/cyto.10161","article-title":"Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood","volume":"49","author":"Rosenberg","year":"2002","journal-title":"Cytometry"},{"key":"10.1016\/j.ygyno.2012.11.011_bb0040","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.ygyno.2012.11.011_bb0045","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S1470-2045(12)70372-8","article-title":"Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study","volume":"13","author":"Olmos","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2012.11.011_bb0050","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(91)90123-G","article-title":"Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of CsA","volume":"66","author":"Friedman","year":"1991","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2012.11.011_bb0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.gde.2010.10.010","article-title":"Utilizing circulating tumor cells: challenges and pitfalls","volume":"21","author":"Attard","year":"2010","journal-title":"Curr Opin Genet Dev"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812008773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812008773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:26:31Z","timestamp":1531992391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812008773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0090825812008773"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.11.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}